Targets › ZIP
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Jan 2027.
Transcription repressor that specifically binds the 5'-GGAG[GA]A[GA]A-3' consensus sequence. Represses transcription by recruiting the chromatin multiprotein complex NuRD to target promoters. (UniProt, Q8N5A5)
Open in Phaseline: the race on ZIP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Zinc Zinc supplementation; mechanism in IPF unclear but may involve antioxidant and anti-inflam | ZIP | Phase 2 | Idiopathic Pulmonary Fibrosis | Jan 2027 |
Idiopathic Pulmonary Fibrosis (1)
small molecule (1)
Cedars-Sinai Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.